Skp2 inhibitor C1 (SKPin C1)

Catalog No.S8652 Batch:S865201

Print

Technical Data

Formula

C18H13BrN2O4S2
Molecular Weight 465.34 CAS No. 432001-69-9
Solubility (25°C)* In vitro DMSO 93 mg/mL (199.85 mM)
Water Insoluble
Ethanol Insoluble
In Vivo (Add solvents to the product individually and in order.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO Corn oil

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 1.200mg/ml (2.58mM) Taking the 1 mL working solution as an example, add 50 μL of 24 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Skp2 inhibitor C1 (SKPin C1) is a specific and selective small-molecule inhibitor of Skp2-mediated p27 degradation by reducing p27 binding through key compound-receptor contacts.
Targets
p27 degradation
In vitro Skp2 inhibitor C1 treatment of MCF-7 breast cancer cells lines does not increase, but rather decrease the percentage of cells in G1 while increasing the G2/M population.

Protocol (from reference)

Cell Assay:

[1]
  • Cell Lines

    501 Mel cells

  • Concentrations

    10 μM

  • Incubation Time

    16 h

  • Method

    501 Mel cell lines are pretreated with each inhibitor (10 μM) or 0.1% DMSO (vehicle) for 16 h. Cycloheximide half-life is examined.

References

  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530153/

Sellecks Skp2 inhibitor C1 (SKPin C1) Has Been Cited by 11 Publications

Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer [ Cell Rep Med, 2025, S2666-3791(25)00231-9] PubMed: 40449480
SKP2 ubiquitylation modifies IDH1 to regulate hepatoblastoma cell cycle and glucose metabolism [ BMC Cancer, 2025, 25(1):1304] PubMed: 40790564
SCF-SKP2 E3 ubiquitin ligase links mTORC1/ER stress/ISR with YAP activation in murine renal cystogenesis [ The Journal of Clinical Investigation, 2022-, -Volume 132, Issue 24] PubMed: None
SCF-SKP2 E3 ubiquitin ligase links mTORC1-ER stress-ISR with YAP activation in murine renal cystogenesis [ J Clin Invest, 2022, e153943] PubMed: 36326820
Nascent transcriptome reveals orchestration of zygotic genome activation in early embryogenesis [ Curr Biol, 2022, 32(19):4314-4324.e7] PubMed: 36007528
Tyrphostin AG1024 Suppresses Coronaviral Replication by Downregulating JAK1 via an IR/IGF-1R Independent Proteolysis Mediated by Ndfip1/2_NEDD4-like E3 Ligase Itch [ Pharmaceuticals (Basel), 2022, 15(2)241] PubMed: 35215353
Genetic screens identify a context-specific PI3K/p27Kip1 node driving extrahepatic biliary cancer [ Cancer Discov, 2021, candisc.0209.2021] PubMed: 34282029
Genetic Screens Identify a Context-Specific PI3K/p27Kip1 Node Driving Extrahepatic Biliary Cancer [ Cancer Discov, 2021, 11(12):3158-3177] PubMed: 34282029
S-phase kinase-associated protein-2 (Skp2) promotes nucleus pulposus cell proliferation by inhibition of p27 in attenuating intervertebral disc degeneration [ Eur Rev Med Pharmacol Sci, 2020, 24(6):2802-2810] PubMed: 32271397
SKP2 targeted inhibition suppresses human uveal melanoma progression by blocking ubiquitylation of p27. [ Onco Targets Ther, 2019, 12:4297-4308] PubMed: 31213847

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.